Skip to main content

Remote Job Finders (RJF)

From Weight Loss to Hair Loss: The Search for the Next Blockbuster

A new generation of companies is eyeing the existing, sizeable hair loss market, hoping that better formulations and new scientific targets will finally produce treatments that are safer and more effective, as well as commercially successful.

Novo CEO Fires Back at Pfizer From White House: ‘Put Your Hand in Your Pocket’

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ongoing bidding war between Novo Nordisk and Pfizer over obesity biotech Metsera.

The GLP-1 Paradox—Why Is a $95B Obesity Market Ignoring Its Biggest Problem?

The nausea and other gastrointestinal side effects of weight loss drugs like Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound will limit how much these drugs can help patients and stunt the overall obesity market unless we approach the problem head on.
Scroll to top